Crinetics Pharmaceuticals (CRNX) Capital Expenditures (2017 - 2026)

Crinetics Pharmaceuticals' Capital Expenditures history runs 10 years deep, the most recent figure standing at $464000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 75.76% year-over-year to $464000.0; the TTM figure through Mar 2026 stood at $589000.0 (down 78.78% YoY), while the FY2025 annual figure was $389000.0, down 89.88% from the prior year.
• Capital Expenditures for Q1 2026 stood at $464000.0, up from $332000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $4.2 million in Q2 2025, with the low at -$4.4 million in Q3 2025.
• The 5-year median for Capital Expenditures is $264000.0 (2025), against an average of $327588.2.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures slumped 7777.78% in 2022, then jumped 8225.0% in 2024.
• Crinetics Pharmaceuticals' Capital Expenditures stood at -$1.4 million in 2022, then surged by 132.2% to $445000.0 in 2023, then soared by 749.89% to $3.8 million in 2024, then sank by 91.22% to $332000.0 in 2025, then surged by 39.76% to $464000.0 in 2026.
• Business Quant data shows CRNX's Capital Expenditures at $464000.0 in Q1 2026, $332000.0 in Q4 2025, and -$4.4 million in Q3 2025.